ESMO: AstraZeneca and Daiichi Sankyo’s Enhertu achieved a 61.6% PFS

13 September 2024

Among the first presentations at the European Society for Medical Oncology (ESMO) meeting that kicked off today, were results from the DESTINY-Breast12 Phase IIIb/IV trial of Enhertu (trastuzumab deruxtecan).

The data showed that Enhertu demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2-positive metastatic breast cancer who have brain metastases and received no more than two prior lines of therapy in the metastatic setting.

Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Japan’s Daiichi Sankyo (TYO: 4568) and being jointly developed and commercialized with UK pharma major AstraZeneca (LSE: AZN).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology